Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Business Wire
PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival rate compared to historical controls in Novocure’s phase 2 pilot trial in advanced pancreatic cancer ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it has received a U.S. Food and Drug Administration Investigational Device Exemption (IDE) approval to initiate its PANOVA 3 clinical trial. The randomized phase 3 pivotal trial is designed to determine the efficacy and safety of Tumor Treating Fields (TTFields) with nab-paclitaxel and gemcitabine as a front-line treatment for unresectable locally advanced pancreatic cancer. PANOVA 3
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024Business Wire
- NovoCure Limited (NASDAQ: NVCR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock, up previously from $25.00.MarketBeat
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024Business Wire
- NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an "overweight" rating on the stock.MarketBeat
NVCR
Earnings
- 2/22/24 - Beat
NVCR
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- 4/12/24 - Form PRE
- NVCR's page on the SEC website